Drs. Pedro Barata, Brad McGregor, Neil Shah, and Michael Serzan discuss how frontline treatment selection in advanced clear cell RCC depends on balancing long-term disease control with the need for rapid tumor response. They review the tradeoffs between Ipi-Nivo and IO-TKI combinations, emphasizing that symptomatic disease burden, comorbidities, and metastatic sites such as bone, liver, or brain can strongly influence regimen choice. The discussion highlights that while several effective options exist, the best approach is often individualized based on the patient’s clinical presentation and treatment goals.
Contributors:
Dr. Pedro Barata is a medical oncologist in Cleveland, Ohio and is affiliated with University Hospitals Cleveland Medical Center.
Dr. Bradley McGregor is a medical oncologist at Dana-Farber in Boston.
Dr. Neil Shah is a medical oncologist at Memorial Sloan Kettering Cancer Center.
Dr. Michael Serzan is a medical oncologist at Dana-Farber in Boston.
